The tragic past
Thalidomide was first synthesized in 1953 by Ciba and then in 1954 by Kunz, a chemist at the German Chemie Grunenthal pharmaceutical company. 1 On October 1957, it was placed on the market as a therapy for insomnia and antiemetic agent for pregnant women, and gained widespread popularity in Europe and most industrialized nations. It lacked the typical addictive properties of barbiturates and produced a natural, calm sleep, and hence was believed to be basically nontoxic compared with other sedatives. By 1960, thalidomide was being sold by Chemie Grunenthal and its licensees in more than 40 countries and had become a popular sedative and morning-sickness treatment during the first trimester of pregnancy.
In November 1961, Widukind Lenz, a German physician and genetist, after examining more than 50 malformed infants whose mothers had taken the drug during pregnancy, asserted that thalidomide was severely teratogenic. 2 In the December of the same year, the same opinion was expressed by William Mc Bride 3 and worldwide confirmation of their conclusions resulted in withdrawal of the drug in most countries by the end of the year. Its status as a powerful teratogen was soon evident and nearly 10 000 infants were affected. Their abnormalities included absence of ears and arms, deafness, phocomelia, facial and palatal defects and GI malformations. Approximately 40% died within the first year of life. [4] [5] [6] Thalidomide (a-N-[phthalimido] gluramide) is a derivative of glutamic acid. Structurally, thalidomide is a system containing two imide rings (phthalimide and glutarimide) and a single chirol centre (ref. Thalidomid). The current available formulation is a racemic mixture; at physiological pH, thalidomide is present as the optical active S and R isomers 7 The S isomer has been associated with its teratogenicity, while the R isomer is primarily responsible for its sedative properties. 1 
Thalidomide in the treatment of erythema nodosum leprosum (ENL) and other diseases
In 1965, Sheskin reported that thalidomide was dramatically effective in the management of ENL. 8 In 1998, it was approved by the US Food and Drug Administration (US FDA) for the initial therapy and maintenance of severe ENL and for the prevention and suppression of its recurrent cutaneous manifestations.
Today thalidomide is being clinically evaluated or used compassionately in more than 30 nonmalignant conditions, including dermatological, infectious and autoimmune disorders. 9 -11 It appears particularly promising for the management of HIV-related complications, including aphthous and oesophageal ulcers, and wasting syndromes, [12] [13] [14] cutaneous lesions of systemic lupus erythematosus 15 and cutaneous and pulmonary sarcoidosis. 16 Interest in the drug has also been renewed by demonstration of its activity in chronic graft-versus-host disease, 17, 18 although poor tolerance frequently limits its use.
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Thalidomide as an anticancer agent Thalidomide was first studied as an anticancer agent as early as 1962 when it was used by Woodyatt 20 to treat a mixed mesodermal tumour of the uterus. Three clinical trials were performed in the early 1960s, including a study by the Eastern Cooperative Oncology Group. 21, 22 Thalidomide has displayed limited therapeutic activity in the management of recurrent glioma, breast cancer, melanoma, renal and ovarian cancer and hormone-refractory prostate cancer, [23] [24] [25] [26] but has proved strikingly effective against AIDSrelated Kaposi's sarcoma. 27 It also halts weight loss and improves sleep in most cancer patients. 28 
Angiogenesis in haematological malignancies
Solid tumour growth consists of an avascular and a subsequent vascular phase. Assuming that the latter process is dependent on angiogenesis and depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumour growth and metastasis. 29 Practically all solid tumours, including tumours of the colon, lung, breast, cervix, bladder, prostate and pancreas, progress through these phases.
While it is well established that the growth of solid tumours is angiogenesis dependent, 29 it had been assumed that leukaemias and other haematological malignancies were not. The role of angiogenesis in growth and survival of these tumours has only been realized in the past 10 years. In 1994, it was demonstrated that the progression of several haematopoietic cancers is clearly related to the degree of angiogenesis, and subsequent studies have confirmed this. 30 Thalidomide's antiangiogenic activity
The exact reason why thalidomide causes limb defects remained unknown until Folkman's group identified its antiangiogenic effects. Given that development of foetal limbs is heavily dependent on the formation of new blood vessels, this is at least in part the reason why such defeats were observed. 31 D'Amato and collaborators used a rabbit cornea micropocket assay in which angiogenesis was induced by fibroblast growth factor-2 (FGF-2) in order to demonstrate that thalidomide inhibits angiogenesis mainly by directly preventing new vessel formation as opposed to suppression of infiltrating host inflammatory cells. 31 Histological sections of the pretreated neovascularized corneas were virtually free of inflammatory cells. Later, the same group reported that thalidomide inhibited vascular endothelial growth factor (VEGF) in a murine model of corneal vascularization 32 and others have shown that it inhibits microvessel formation in a rat aorta ring assay. 33 Moreover, D'Amato found thalidomide inhibits the growth of V2 carcinoma in rabbits by an antiangiogenic mechanism. 34 
Alternative mechanisms of action
The precise mechanism of action of thalidomide has been difficult to elucidate because of its relative lack of activity in vitro compared to effects in vivo, and the fact that in solutions at physiologic pH, it undergoes spontaneous nonenzymatic hydrolysis into numerous metabolities. 1 The immunomodulatory effects of thalidomide depend on the drug's inhibition of tumour necrosis factor alpha (TNF-a) 35 and suppression of nuclear factor kappa B (NF-kB) activation in response to inflammatory agents. 36, 37 By acting as a costimulator, thalidomide increases the response of T cells to T-cell receptor-mediated stimulation, yielding increased proliferation and greater production of interleukin-2 (IL-2), IL-10 and interferon gamma (IFN-g). 9, 38, 39 Thalidomide increases the number of natural killer cells, while these cells exhibit augmented cytotoxic activity against tumour cells. 40 In addition, it downregulates IL-5, IL-6, IL-8 and IL-12 production. [41] [42] [43] A downregulation of adhesion molecules and a decrease in cell-cell contact between human T leukaemic cells and human umbilical vein endothelial cells has been demonstrated after exposure to thalidomide. 44 Adhesion molecules are involved by facilitating the adherence of tumour cells to the endothelium and are required for the development of metastases. Thalidomide also induces tumour cell apoptosis, as evidenced by increased sub-G1 cells for the induction of p21 and growthrelated arrests. 45 Thalidomide in the treatment of haematological malignancies
Multiple myeloma (MM)
Since thalidomide possessed antiangiogenic properties, Singhal et al 46 used it on a compassionate basis to treat 84 patients with relapsed and refractory MM in late 1997 and found it remarkably affective with an MR þ PR þ CR rate of 32%. Thalidomide was thus the first new drug to display significant single-agent activity against relapsed and relapsed refractory MM in more than 30 years. It was administered for a median of 80 days at an initial dose of 200 mg taken at night, augmented by 200 mg every 2 weeks to a maximum of 800 mg. Response was defined as 425% reduction in serum or urine levels of paraprotein and was typically apparent within 2 months. A 90% reduction was documented in eight patients (with two achieving complete response), as reflected by disappearance of paraprotein in both serum and urine. Decreases in plasma cell infiltration of bone marrow and increased haemoglobin values were observed in 78% of the responders, although no difference in the bone marrow microvascular density was found between responsive and resistant patients. However, only a subset of patients had bone marrow serially assessed for angiogenesis, limiting the strength of this observation to truly rule out any antiangiogenic effect against new vessel formation. While inhibition of new vessel formation remains an attractive potential mechanism of action, thalidomide has a number of other properties that may explain its activity in MM. These include disruption of adhesion molecule expression and as a result, the interaction of myeloma cells with the bone marrow microenvironment. 47 This decreases the secretion of cytokines that augment growth and survival 48, 49 and drug resistance. 50 Thalidomide also induces dose-dependent modulation of TNF-a production by stimulated monocytes, macrophages and neutrophils, 51 with no effect on total protein synthesis or the production of other cytokines. Finally, thalidomide has been shown to enhance cell-mediated immunity by direct costimulation of T cells. 52 These effects are also accompanied by means of the T-cell receptor complex, thereby increasing IL-2-mediated cell proliferation and IFN-g production. IL-6 is a major growth survival and drug-resistant factor in MM 53 and its suppression by thalidomide inhibits plasma cell growth.
Subsequent studies have shown that thalidomide is active in relapsed MM with response rates ranging from 25 to 35% [54] [55] [56] [57] and a median response duration of approximately 12 months. 55, 57 Thalidomide has also shown to be useful in early stage of myeloma and is being assessed for the treatment of both newly diagnosed symptomatic patients and those with smouldering disease. [58] [59] [60] [61] Mohty et al 62 demonstrated that singleagent thalidomide is potentially effective in MM patients who progress after allogenic stem cell transplant, confirming a prior study by Richardson et al 63 in which both patients relapsing after autologous stem cell transplant and allogenic stem cell transplant responded to dose escalation. In this latter study, dose dependent as well as cumulative toxicity was observed with the authors concluding that doses should be individualized according to response and tolerance with a median dose of 200 mg/day administered in this study.
Combination therapy
Thalidomide has also been combined with other active agents in the management of relapsed MM, while the absence of myelosuppression and other important adverse effects suggests that it could be combined with chemotherapy. Combination with other agents has produced higher overall response rates (defined as a greater than 50% reduction in myeloma paraprotein levels) in relapsed and relapsed, refractory myeloma, with a mean of RR of 36% with thalidomide alone, compared to 52% when combined with dexamethasone and 62% when combined with dexamethasone and chemotherapy. 64 Importantly, after myeloablative therapy for MM, it has been shown that progression-free survival is shorter for disease in partial remission as compared to complete remission. 64 In an attempt to induce more durable remission, thalidomide plus dexamethasone has thus been employed in patients with partial remission after intensive therapy. 65 The combination reduced tumour mass in 57% of patients and this may have resulted in longer disease-free survival with preservation of tumour sensitivity to treatment with previously effective drugs also suggested in this study. 65 When given within 15 months after intensive therapy, thalidomide plus dexamethasone, provided myeloma protein production has been reduced by 475%, kept it at a constant level for at least 4 months, and markedly reduced the tumour mass in 57% of patients, with stable, residual disease. The combination has also been evaluated for the primary management of active MM 66 and untreated symptomatic forms 61 and appears especially active in the context of a recently completed ECOG trial. 67 Palumbo et al 68 compared the clinical outcome of patients with relapsed/refractory MM with that of a control group treated with conventional chemotherapy and demonstrated that as first salvage regimen, thalidomide-dexamethasone was superior to conventional chemotherapy, while as second or third salvage regimen, it was equivalent to conventional chemotherapy.
Thalidomide plus cyclophosphamide and dexamethasone is active in 77% of patients. 69 The addition of etoposide increases this figure to 86%. 70 Anthracyclines are associated with a greater risk of thalidomide-induced deep-vein thrombosis (DVT). 71 Bortezomib (previously denoted PS-341) is a novel proteasome inhibitor recently approved by the US FDA for the therapy of patients with progressive MM after previous treatment. 72, 73 This drug has also been approved by the EMEA and most recently with the results of the APEX study has been shown to be effective in the treatment of first relapse. Importantly, Bortezomib alone or in combination with dexamethasone and thalidomide has since demonstrated remarkable therapeutic activity in heavily pretreated patients with advanced MM including patient who have had prior thalidomide and bortezomib as single agents. 74 This represents an important paradigm shift supporting the use of combinations of biological therapies for the treatment of MM patients.
Side effects
Side effects associated with thalidomide include sedation, fatigue, constipation, tremor, dizziness, bradycardia and skin rashes. These effects are generally mild, but may affect a patient's quality of life and lead to the discontinuation of treatment, especially when high doses are used. Peripheral neuropathy also limits long administration. DVT is usually observed when thalidomide is administered to previously untreated patients in combination with dexamethasone, doxorubicin or melphalan. Its incidence rises from only 1 to 3% for thalidomide alone, to between 10 and 15% when combined with dexamethasone, and up to approximately 25% when thalidomide is combined with other cytotoxic agents, particularly doxorubicin.
Side effects are typically reversible and disappear after decreasing dose and/or drug suspension. In the Singhal study, median duration of treatment with thalidomide was 80 days and most patients received daily doses of 400 mg, with fewer retaining 600 and 800 mg daily. 46 Subsequent studies have shown doses of 100-200 mg/day being better tolerated. 75 To minimize complications including weakness, fatigue and somnolence, thalidomide is typically administered as a onetime dose in the evening, with a gradual increase of the dose titrated to response and tolerability as the risk of peripheral neuropathy increases both with prolonged exposure and higher dose. Given the risk of accumulative toxicity and neuropathy, particularly with the advent of other agents that are both effective but nonetheless have the possibility of overlapping toxicity with thalidomide, prolonging therapy in the context of established neuropathy, for example, should be avoided. 75 
Leukaemia
Thalidomide's metabolites have cytotoxic effects on leukaemic cells through induction of their morphological differentiation in vitro. 76 The efficacy and tolerability of thalidomide in refractory and relapsed acute and chronic myelogenous leukaemia have been assessed. A phase I-II trial conducted by Steins et al 77 during which 200-400 mg thalidomide daily were administered for 7 weeks (on average) produced a 39% partial response characterized by 450% reduction of blasts and significant lowering of bone marrow microvascular density. Serum levels of FGF-2 and VEGF levels were also reduced.
Waldenströ m's macroglobulinaemia
A 25% partial response was obtained in prospective phase II study of thalidomide in patients with symptomatic Waldenströ m's macroglobulinaemia, 78 and a 30% response was achieved when it was combined with anti-CD20 monoclonal antibody. 79 BLT-D, a nonmyelosuppressive combination composed of clarithromycin, low-dose thalidomide and dexamethasone, has also been used. 80 
Myelodysplastic syndromes
Raza et al 81 obtained a 41% partial remission with thalidomide plus topotecan, pentoxyphylline and/or etanercept (a subcutaneously administered biological response modifier that binds and inactivates TNF-a). In a subsequent study, thalidomide was given at 100-400 mg daily for 12 weeks. 81 Approximately, 50% of patients achieved a partial remission with an increase in haemoglobin, platelets, and absolute neutrophil count, improvement of marrow dysplasia and no need for blood transfusions. A decrease in serum TNF-a and bone marrow microvascular density provided further evidence of the drug's antiangiogenic activity. Strupp et al 82 studied 34 patients who received 100 mg thalidomide daily with a weekly increase of 100 mg daily to 400 mg daily (the maximum-tolerated dose): 66% responded, 20% progressed and 14% remained stable.
Non-Hodgkin's lymphoma
Wilson et al 83 evaluated thalidomide (200 mg daily with a 100 mg daily increment to a maximum of 800 mg daily for 2 months) in a patient with mantle-cell non-Hodgkin's lymphoma resistant to conventional chemotherapy. The CBC was improved and there was a 50% reduction of splenomegaly and abdominal lymphoadenopathy. Bone marrow osteomedullary biopsies revealed a distinct decrease in tumour infiltrate.
Myelofibrosis
One of the first report was provided by Barosi et al, 84 who treated 21 patients with escalating doses of thalidomide, starting at 100 mg daily. A total of 61.5% patients had responses, as evidenced by improvements in anaemia, thrombocytopenia, leucocytosis or spleen size. Similar results were reported by Elliott et al, 85 who treated 15 patients with thalidomide at a starting dose of 200 mg daily. Reduction in plasma levels of VEGF and FGF-2 and bone marrow microvessel density have been reported in certain responders to thalidomide treatment, 86 although the majority of studies conducted to date have been unable to establish a correlation between clinical response and reduced levels of angiogenesis markers.
Amyloidosis
To test the toxicity and efficacy of thalidomide in primary amyloidosis, a phase I-II trial has been performed on patients, the majority of whom had failed prior therapy with high-dose melphalan and autologous stem cell transplantation. 87 In all, 25% patients had a significant reduction in Bence-Jones proteinuria, but severe toxicity was observed in 50% patients. Dispenzieri et al 88 reported adverse reaction in 75% patients. More recently, Palladini et al 89 evaluated the combination of thalidomide and intermediate-dose dexamethasone in 31 patients with primary amyloidosis who did not respond to, or whose disease relapsed after, first-line therapy. They observed that 48% patients achieved haematologic response with 19% complete remission and 26% organ responses and suggested that the combination of thalidomide and dexamethasone may represent a valuable second-line treatment for primary amyloidosis.
Thalidomide analogues
Two classes of thalidomide analogues have been synthesized, namely phosphodiesterase 4 inhibitors that inhibit TNF-a but do not enhance T-cell activation (selected cytokine inhibitory drugs: SelCiDs) and analogues that stimulate T-cell proliferation as well as IL-2 and IFN-g production (immunomodulatory drugs: IMiDs). 90 The activity of thalidomide and that of its metabolities on HUVEC proliferation overlap in vitro, whereas the metabolities are four to five times more active inhibitors of angiogenesis in the CAM assay. 91 Two IMiDs, CC-5013 (Revlimid, lenalinomide) and CC-4047 (Actimid), display antimyeloma activity. 92, 93 By modifying thalidomide structure through the addition of an amino group at the fourth position of the phthaloyl ring (to generate CC-4047) and with the further removal of a carbonyl on the ring to form CC-5013, such analogues are up to 50 000 times more potent at inhibiting TNF-a than the thalidomide parent compound in vitro and are markedly more stable. 94 CC-5013 is clinically active even in thalidomide-resistant patients, is not teratogenic in in vivo preclinical models and its adverse-event profile is free from thalidomide's tendency to produce peripheral neuropathy, somnolence and constipation. 94 Its proposed mechanisms of action also include direct antiproliferative and proapoptotic effects on MM cells through inhibition of NF-kB transcriptional activity and activation of death receptor/caspase-8-mediated death signalling, 95 modulation of MM-bone marrow stromal cell adhesive interactions and abrogation of secretion of prosurvival cytokines, 45 and stimulation of natural killer cell number and cytotoxic activity against MM cells. 40 It is thus a promising agent for the treatment of MM and trials conducted for approval by the FDA are under way. The first phase I study of CC-5013 was carried out in 2001, when a dose range of 5-50 mg daily was tested in 25 patients with relapsed and refractory MM. 94 No significant constipation or neuropathy was seen and encouraging responses were seen in 17 (71%) patients, including 11 patients (46%) who had received prior thalidomide. CC-5013 was further investigated, either alone or in combination with dexamethasone, to treat patients with MM at first relapse, or for relapsed-refractory MM (Richardson P et al. Blood 2003; 102: 825a; abstract). Additional clinical phase II trials have confirmed these data, achieving impressive responses with a favourable side-effect profile, and two clinical phase III trials comparing CC-5013 combined with high-dose dexamethasone to high-dose dexamethasone alone have recently been completed. 96 Preliminary analysis has confirmed markedly superior outcome for the combination both in terms of time to progression and response rate, but the sideeffect profile was noteworthy for a high rate of DVT and pulmonary embolus at 14%, a finding which was a surprise given the absence of thromboembolic complications seen with CC-5013 alone.
The effects of combining CC-5013 with rapamycin, a specific mTOR inhibitor, have been studied preclinically, based on rational targeting of the differential signalling cascade-mediating MM cell growth and survival. 97 Results have shown synergy between these two orally bioavailable agents and suggest that low-dose combinations may be effective. It should be noted that this in vitro work has not yet been tested in vivo. Clinically, studies will need to be approached with caution due to the fact that both of these agents are toxic for endothelial cells and thus vascular injury may be considerable.
In a preliminary report, six out nine patients with myelodysplastic syndrome treated with CC-5013 at the dose of 25 mg daily achieved haematological benefits, including transfusion independence, reduction of bone marrow blasts and cytologic dysplasia and improvement in marrow multipotent and erythroid progenitor formation. 98 Schey et al 99 reported data from a phase I study addressing the tolerability, efficacy and immunologic effects of CC-4047 in the treatment of patients relapsed or relapsed refractory MM, and results suggest that this agent appears very active but is associated with significant toxicity, including DVT, even when used as a single agent.
The proteasome inhibitor bortezomib in preclinical studies, appears not only to have activity against MM cells but also to downregulate protective interactions with bone marrow stromal cells and to inhibit angiogenesis, and is now undergoing clinical evaluation in combination with thalidomide and CC-5013 for the treatment of MM patients in their earlier disease course. 100 
Concluding remarks
Thalidomide's potential in haematological malignancies and other diseases appears to be related to its inhibition of angiogenesis, regulation of TNF-a synthesis, significant effects on microenvironment and immunomodulatory properties (Table 1) . Data from clinical trials indicate that it has important toxicities that are generally manageable. However, neurological toxicity in particular represents an ongoing clinical challenge for most practitioners administering thalidomide and this side effect is especially difficult to treat once it becomes established. In fact, treatment emergent peripheral neuropathy in particular with long-term use necessitates the discontinuation of the therapy or dose reduction. Nonetheless, thalidomide alone or in combination is now considered standard therapy for relapsed and refractory MM. Importantly, thalidomide analogues appear to have significantly greater potency than thalidomide with a more favourable side effect profile, and these new agents have important implications for changing the current paradigm of antimyeloma therapy.
Continued study of thalidomide is warranted, especially with laboratory correlates to further elucidate its mechanisms of action and to determine the ideal dosing schedule, duration of therapy enrolment and overall maintenance therapy. Of special interest will be its role in combination with both standard agents and new drugs. Further clinical evaluation of thalidomide in MM and other haematologic malignancies should provide new insights and the promise of improved outcome, but patients and physicians must continue to exercise caution regarding its sideeffect profile, including its teratogenicity. 
